On the basis of this preclinical study, two EGFR-mutated, RET-fused NSCLC patients benefited from the combination therapy of osimertinib and BLU-667 with a tolerable profile and rapid radiographic response [89]. Here, EGFR is linked to non-small cell lung carcinoma.